[Clobazam (Frisium) in everyday practice. An open six-months' study of its efficacy and tolerance (author's transl)].
Fifty patients suffering principally from neurotic and psychosomatic disturbances were treated for 6 months with an average of 30 mg clobazam (Frisium) per day. For documentation of the efficacy and tolerance a set of assessment scales and procedures from the ECDEU system (Early Clinical Drug Evaluation Unit) was compiled. The results showed unanimously the anxiolytic efficacy and good tolerance of clobaza. After the second week of treatment there was a significant reduction in the anxiety symptoms in the judgement of the doctor and patient (p less than 0.01). Parallel to the reduction of anxiety symptoms the general condition also improved. The good tolerance of clobazam was shown in the overall clinical assessment and in the recording of specific side effects, which could never be called severe in any case. Moreover, there were no suggestions of changes in tolerance of of dependency.
D000328:Adult; D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001007:Anxiety / Q000188:drug therapy; D001569:Benzodiazepines; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009497:Neurotic Disorders / Q000188:drug therapy*; D011569:Psychiatric Status Rating Scales; D011602:Psychophysiologic Disorders / Q000188:drug therapy*
D014151:Anti-Anxiety Agents; D001569:Benzodiazepines
Clobazam (Frisium) in der täglichen Praxis Offene Halbjahresstudie zur Wirksamkeit und Verträglichkeit.